Ritonavir Completed Phase 3 Trials for Human Immunodeficiency Virus Type 1 (HIV-1) Infection Treatment

clinicaltrials.gov IdentifierTitleDrugs
NCT02652624Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected Women
NCT01966822Multicentre Study To Assess Changes In Bone Mineral Density Of The Switch From Protease Inhibitors To Dolutegravir In HIV-1-Infected Subjects With Low Bone Mineral Density
NCT01511809Efficacy of Atazanavir/Ritonavir Monotherapy as Maintenance in Patients With Viral Suppression
NCT01352715Study of Options for Second-Line Effective Combination Therapy (SELECT)
NCT00450580HIV-1 Infection Study of Once a Day Versus Twice a Day Protease Inhibitor in Antiretroviral Treatment Naive Adults
NCT01033760Optimisation of Primary HIV1 Infection Treatment(ANRS 147 OPTIPRIM)